Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Acrocephalosyndactylia × Rabeprazole × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Stomach Neoplasms 3 Small Cell Lung Carcinoma 1 Non-Erosive Reflux Disease 1 Neoplasms 1 Lung Neoplasms 1 Helicobacter Infections 1 Gastrointestinal Hemorrhage 1 Gastroesophageal Reflux 1 Gastritis, Atrophic 1 Dyspepsia 1 Carcinoma, Non-Small-Cell Lung 1 Barrett Esophagus 1 Adenocarcinoma 1 Acrocephalosyndactylia 1

Interventions

lenvatinib 1 infigratinib 1 brivanib 1 Rogaratinib 1 Rabeprazole 1 Irinotecan 1 E-3810 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02747797 2018-08-02

Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations

University of California, San Diego

Phase 2 Withdrawn

Acrocephalosyndactylia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡